Valbiotis (XPAR:ALVAL) Interest Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XPAR:ALVAL Valbiotis SA XPAR:ALVAL
60 GF Score
Price €0.79
GF Value €1.48
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Valbiotis Interest Received?

Interest Received only applicable to companies reporting Cash Flow from Operations in direct method.

XPAR:ALVAL
60GF Score
Valbiotis SA XPAR:ALVAL
Interest Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Valbiotis (XPAR:ALVAL) Overvalued in 2026?

Based on GuruFocus' analysis, Valbiotis stock appears to be undervalued. The current stock price of €0.79 is trading 46.6% below its estimated GF Value™ of €1.48. GuruFocus considers Valbiotis to be Possible Value Trap.

Key valuation signals for XPAR:ALVAL:

  • Interest Received:
  • GF Value™: €1.48 vs. price of €0.79 (46.6% below fair value)
  • GF Score™: 60/100 with 6 warning signs

No single metric tells the full story. See the XPAR:ALVAL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Valbiotis Business Description

Other Exchanges 8JD:Germany
Address 12F rue Paul VATINE, Perigny, La Rochelle, FRA, 17180
Valbiotis SA is a research & development company. It is engaged in scientific innovation for preventing and combating metabolic diseases. Valbiotis has adopted an approach, aiming to revolutionize healthcare by developing a new class of Nutrition Health products designed to reduce the risk of metabolic diseases, based on a multi-target approach by the use of plant-based ingredients.
60GF Score

Get the complete analysis for XPAR:ALVAL

Interest Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.79
Price
€1.48
GF Value